Understanding the Link Between Helicobacter pylori and CRC

Epidemiological evidence increasingly suggests that Helicobacter pylori and CRC share a complex pathological relationship. While H. pylori is a well-known risk factor for gastric malignancies, its role in colonic oncogenesis has remained largely elusive until recently. Researchers have now utilized advanced RNA sequencing data from GEO and TCGA databases to map the shared molecular signatures between H. pylori infection (HP-I) and colorectal cancer (CRC).

Analysis of gene expression profiles revealed 112 shared differentially expressed genes (DEGs) common to both conditions. Among these, 74 genes showed up-regulation while 38 were down-regulated. Furthermore, functional annotation suggests these genes predominantly orchestrate immune responses and chronic inflammatory pathways. Consequently, the persistent inflammation triggered by H. pylori may create a permissive environment for colorectal tumor development. Additionally, this crosstalk facilitates the transition from chronic infection to malignant transformation through specific molecular conduits.

The Diagnostic Role of Hub Genes in Helicobacter pylori and CRC

The study pinpointed eight central hub genes that drive the comorbidity of HP-I and CRC. These genes include AGT, CCL20, CXCL1, CXCL2, CXCL5, CXCL9, CXCL10, and MMP9. Notably, these markers demonstrated exceptional diagnostic performance in identifying CRC. Statistical validation showed Area Under the Curve (AUC) values ranging from 0.682 to 0.933, indicating their high reliability as clinical biomarkers. Specifically, CXCL1 and CXCL9 emerged as critical prognostic markers, suggesting that their expression levels could predict long-term patient outcomes.

Moreover, immune infiltration analysis highlighted a significant dysregulation of CD4⁺ T cell subsets in patients with both conditions. This shift in the immune microenvironment likely impairs the body's ability to eliminate early-stage cancerous cells. Beyond diagnostics, the study used the CMap database to screen for therapeutic candidates. As a result, researchers identified DY-131 as a potential small-molecule compound that could target these shared molecular pathways. This discovery offers a promising avenue for future precision medicine strategies in treating CRC patients with a history of chronic H. pylori infection.

Frequently Asked Questions

Which genes link H. pylori to colorectal cancer?

Research identifies eight primary hub genes—AGT, CCL20, CXCL1, CXCL2, CXCL5, CXCL9, CXCL10, and MMP9—as the central players linking the two conditions through inflammatory and immune-related pathways.

Can these genes predict CRC outcomes?

Yes, specifically CXCL1 and CXCL9 have been identified as significant prognostic markers. Their expression levels help clinicians determine the likely progression and survival outcomes for colorectal cancer patients.

What is DY-131's role in potential therapy?

DY-131 is a small-molecule compound identified through chemical mapping. It shows potential in targeting the shared molecular mechanisms between HP-I and CRC, offering a possible therapeutic candidate for comorbid cases.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wei N et al. Common crosstalk genes and molecular mechanisms in Helicobacter pylori infection and colorectal cancer. Discov Oncol. 2026 Apr 26. doi: 10.1007/s12672-026-04866-9. PMID: 42035394.

Butt J, Varga MG, Wang Y, et al. Association of Helicobacter pylori Antibody Levels with Risk of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1594-1602.

Zhang Y, Han S, et al. Diagnosis and prognostic value of CXC motif chemokine ligand 1 in colon adenocarcinoma. J Cancer. 2021;12(19):5715-5724.